MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Diabetic Autonomic Neuropathy and Left Ventricular Function

Phase 4
Completed
Conditions
Diabetes Mellitus
Interventions
First Posted Date
2023-02-06
Last Posted Date
2023-02-06
Lead Sponsor
AHEPA University Hospital
Target Recruit Count
59
Registration Number
NCT05713396
Locations
🇬🇷

Diabetes Center, 1st Propeudetic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, "AHEPA'' Hospital, Thessaloníki, Greece

Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19

Phase 3
Active, not recruiting
Conditions
COVID-19 Associated Cardiac Involvement
Exercise Intolerance
Remodeling, Left Ventricle
Left Ventricular Dysfunction
Microvascular Angina
Remodeling, Vascular
Vascular Inflammation
Interventions
First Posted Date
2022-11-17
Last Posted Date
2025-04-04
Lead Sponsor
Valentina Puentmann
Target Recruit Count
279
Registration Number
NCT05619653
Locations
🇦🇹

University Medical Centre Vienna, Vienna, Austria

🇩🇪

Institute for experimental and translational cardiovascular imaging, Frankfurt Am Main, Hessen, Germany

🇩🇪

University Hospital Greifswald, Greifswald, Germany

and more 2 locations

Losartan in Prevention of Radiation-Induced Heart Failure

Early Phase 1
Recruiting
Conditions
Breast Cancer
Myocardial Fibrosis
Radiation-Induced Fibrosis
Interventions
Radiation: Radiation Therapy
First Posted Date
2022-11-07
Last Posted Date
2024-01-12
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
10
Registration Number
NCT05607017
Locations
🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies

Phase 4
Recruiting
Conditions
Uric Acid Nephropathy
Interventions
First Posted Date
2022-06-02
Last Posted Date
2022-11-28
Lead Sponsor
Hospital General de Niños Pedro de Elizalde
Target Recruit Count
40
Registration Number
NCT05402397
Locations
🇦🇷

HGNPE, Caba, Argentina

Hypertension in Young Adults Trial

Phase 2
Active, not recruiting
Conditions
Hypertension
Interventions
Device: Home BP monitoring with cuffed device
Device: Home BP monitoring with cuffed device + BP watch
Device: Home BP monitoring with cuffed device + BP patch
First Posted Date
2022-05-11
Last Posted Date
2025-03-27
Lead Sponsor
University of California, San Francisco
Target Recruit Count
120
Registration Number
NCT05370599
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

Cardiorenal Effecs of Losartan in Kidney Transplant Recipients

Conditions
Renal Transplant Failure
Cardiovascular Complication
Interventions
First Posted Date
2022-02-17
Last Posted Date
2022-02-17
Lead Sponsor
Medical University of Gdansk
Target Recruit Count
740
Registration Number
NCT05243446
Locations
🇵🇱

Medical University, Gdansk, Poland

Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty

Phase 4
Withdrawn
Conditions
Arthrofibrosis
Interventions
First Posted Date
2021-12-15
Last Posted Date
2023-12-01
Lead Sponsor
NYU Langone Health
Registration Number
NCT05157464
Locations
🇺🇸

NYU Langone Health, New York, New York, United States

Effects of Angiotensin Converting Enzyme Inhibitors on Patency of Arterio-Venous Fistulas: A Randomized Controlled Trial

Early Phase 1
Conditions
Vascular Access Complication
Interventions
Drug: multi-vitamins
First Posted Date
2021-11-24
Last Posted Date
2021-11-24
Lead Sponsor
Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi
Target Recruit Count
100
Registration Number
NCT05132712
Locations
🇵🇰

Anas Bin Saif, Rawalpindi, Punjab, Pakistan

Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy

Phase 2
Not yet recruiting
Conditions
Breast Cancer
Interventions
First Posted Date
2021-10-28
Last Posted Date
2021-10-28
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
52
Registration Number
NCT05097248
Locations
🇨🇳

Union Hospital, Tongji Medical College of HUST, Wuhan, Hubei, China

Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions

First Posted Date
2021-10-22
Last Posted Date
2021-10-22
Lead Sponsor
Laboratorios Silanes S.A. de C.V.
Target Recruit Count
36
Registration Number
NCT05090449
Locations
🇲🇽

Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico

© Copyright 2025. All Rights Reserved by MedPath